Search all trials

Find therapies in clinical trials near you – page 11

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Neuroendocrine carcinoma

Recruiting

Registered drugNo placebo

Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cisplatin

Contact Research Centre

Study on Luspatercept and Epoetin Alfa for Patients with Low-Risk Myelodysplastic Syndrome Without Ring Sideroblasts Who Did Not Respond to ESA

Recruiting

Registered drugNo placebo

Study on Luspatercept and Epoetin Alfa for Patients with Low-Risk Myelodysplastic Syndrome Without Ring Sideroblasts Who Did Not Respond to ESA

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Epoetin Alfa

Contact Research Centre

Septic shock

Recruiting

Registered drugNo placebo

Study on Landiolol Hydrochloride and Sodium Chloride for Reducing Mortality in Patients with Septic Shock and High Heart Rate

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Sodium Chloride

Contact Research Centre

Non-small cell lung cancer stage IV

Recruiting

Registered drugNo placebo

Study on Maintenance Treatment with Pembrolizumab and Pemetrexed for Stage IV Non-Small Cell Lung Cancer Patients After Initial Chemotherapy and Immunotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Acute lymphocytic leukaemia+1

Recruiting

Registered drugNo placebo

Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Blinatumomab

Contact Research Centre

Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

Not yet recruiting

Registered drugNo placebo

Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Nemtabrutinib

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Registered drug

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab

Contact Research Centre

Triple negative breast cancer

Not yet recruiting

Registered drugNo placebo

Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Registered drugNo placebo

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Non-small cell lung cancer stage III

Not yet recruiting

Registered drugNo placebo

Durvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Colitis ulcerative

Not yet recruiting

Registered drugNo placebo

Safety and efficacy of stopping versus maintenance dose of filgotinib, tofacitinib and upadacitinib in adult ulcerative colitis patients in deep remission

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Filgotinib

Contact Research Centre

Cardiac failure

Not yet recruiting

Registered drugNo placebo

Effect of Acetazolamide Added to Standard Therapy on Weight Reduction and Symptom Relief in Patients with Heart Failure

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acetazolamide

Contact Research Centre

Find therapies in clinical trials near you – page 11

261 trials match your criteria

Neuroendocrine carcinoma

Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

Study on Luspatercept and Epoetin Alfa for Patients with Low-Risk Myelodysplastic Syndrome Without Ring Sideroblasts Who Did Not Respond to ESA

Study on Luspatercept and Epoetin Alfa for Patients with Low-Risk Myelodysplastic Syndrome Without Ring Sideroblasts Who Did Not Respond to ESA

Septic shock

Study on Landiolol Hydrochloride and Sodium Chloride for Reducing Mortality in Patients with Septic Shock and High Heart Rate

Non-small cell lung cancer stage IV

Study on Maintenance Treatment with Pembrolizumab and Pemetrexed for Stage IV Non-Small Cell Lung Cancer Patients After Initial Chemotherapy and Immunotherapy

Acute lymphocytic leukaemia+1

Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

Systemic scleroderma

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Triple negative breast cancer

Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

Hormone receptor positive HER2 negative breast cancer

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Non-small cell lung cancer stage III

Durvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer

Colitis ulcerative

Safety and efficacy of stopping versus maintenance dose of filgotinib, tofacitinib and upadacitinib in adult ulcerative colitis patients in deep remission

Cardiac failure

Effect of Acetazolamide Added to Standard Therapy on Weight Reduction and Symptom Relief in Patients with Heart Failure

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.